ATNF accelerates vesting of 1.36M equity awards; options need shareholder OK

Q: How many 180 Life Sciences (ATNF) options had vesting accelerated?

The Board accelerated vesting of 965,000 stock options granted to executives and non-executive directors.

Q: What is the exercise price of the accelerated options?

All options have an exercise price of $0.9290 per share , the market close on 17 June 2025.

Q: Can the newly vested options be exercised immediately?

No. Shareholder approval of the 2025 Option Incentive Plan is required ; without it, the options will be cancelled.

Q: How many restricted shares vested as a result of the Board action?

A total of 390,329 restricted shares (executive and director grants combined) vested in full on 11-12 July 2025.

Q: What changes were made to Eric Van Lent鈥檚 consulting agreement?

The term was extended to 31 December 2025 and the termination fee increased from $10,000 to $25,000 .

Q: Does the filing affect 180 Life Sciences鈥� cash position?

The actions are primarily non-cash accounting events ; only the higher termination fee could lead to a modest future cash outflow.

[Form 3] Jones Lang LaSalle, Inc. Initial Statement of Beneficial Ownership

Filing Impact

(Low)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

180 Life Sciences Corp. (NASDAQ: ATNF/ATNFW) filed an 8-K on 11-12 July 2025 disclosing compensation-related actions approved by its Board of Directors.

Accelerated vesting 鈥� executives: The Board accelerated in-full vesting of (i) 435,000 stock options (exercise price $0.9290; 10-year term) and (ii) 175,750 restricted shares previously granted on 17 June 2025 to CEO Blair Jordan and CAO Eric Van Lent.
Accelerated vesting 鈥� non-executive directors: Vesting of 530,000 options (same $0.9290 exercise price) and 214,579 restricted shares granted on 17 June 2025 to three independent directors was likewise accelerated.
Shareholder approval still required: Under Nasdaq rules and the company鈥檚 2025 Option Incentive Plan, none of the accelerated options may be exercised until shareholders approve the 2025 Plan. If approval is not obtained within one year of adoption, all options issued under the plan will be cancelled.
Consulting agreement amendment: On 12 July 2025, the company, Eric Van Lent and EVL Consulting, LLC extended Mr. Van Lent鈥檚 Executive Consulting Agreement through 31 Dec 2025 and increased the early-termination fee from $10,000 to $25,000.
No financial or operational metrics were reported.

The filing contains updated exhibits for the 2025 Option Incentive Plan, related award agreements and the amended consulting agreement.

180 Life Sciences Corp. (NASDAQ: ATNF/ATNFW)電� 2025雲� 7鞗� 11-12鞚检棎 8-K 氤搓碃靹滊ゼ鞝滌稖頃橂┌ 鞚挫偓須岇棎靹� 鞀轨澑頃� 氤挫儊甏€霠� 臁办箻毳� 瓿店皽頄堨姷雼堧嫟.

臧€靻嶍檾霅� 氩犾姢韺� 鈥� 鞛勳洂霌�: 鞚挫偓須岆姅 CEO 敫旊爤鞏� 臁半崢瓿� CAO 鞐愲Ν 氚� 霠岉姼鞐愱矊 2025雲� 6鞗� 17鞚检棎攵€鞐悳 (i) 435,000欤� 鞀ろ啞鞓奠厴(頄夓偓臧€瓴� $0.9290, 10雲� 毵岅赴)瓿� (ii) 175,750欤� 鞝滍暅欤检嫕鞚� 鞝勳暋氩犾姢韺呾潉臧€靻嶍檾頄堨姷雼堧嫟.
臧€靻嶍檾霅� 氩犾姢韺� 鈥� 牍勳瀯鞗� 鞚挫偓霌�: 3氇呾潣霃呺 鞚挫偓鞐愱矊 2025雲� 6鞗� 17鞚检棎攵€鞐悳 530,000欤� 鞓奠厴(霃欖澕頄夓偓臧€瓴� $0.9290)瓿� 214,579欤� 鞝滍暅欤检嫕鞚� 氩犾姢韺呺弰臧€靻嶍檾霅橃棃鞀惦媹雼�.
欤检＜鞀轨澑頃勳殧: 雮橃姢雼� 攴滌爼瓿� 須岇偓鞚� 2025 鞓奠厴鞚胳劶韹半笇頂岆灉鞐� 霐半澕, 臧€靻嶍檾霅� 鞓奠厴鞚€ 欤检＜臧€ 2025 頂岆灉鞚� 鞀轨澑頃� 霑岅箤歆€ 頄夓偓頃� 靾� 鞐嗢姷雼堧嫟. 鞀轨澑氚涭 氇豁晿氅� 毂勴儩鞚茧攵€韯� 1雲� 雮挫棎氇摖鞓奠厴鞚� 旆唽霅╇媹雼�.
旎劋韺� 瓿勳暯靾橃爼: 2025雲� 7鞗� 12鞚�, 須岇偓鞕€ 鞐愲Ν 氚� 霠岉姼, EVL Consulting, LLC電� 氚� 霠岉姼鞚� 鞛勳洂旎劋韺� 瓿勳暯鞚� 2025雲� 12鞗� 31鞚缄箤歆€ 鞐办灔頃橁碃臁瓣赴頃挫 靾橃垬耄岆ゼ $10,000鞐愳劀 $25,000搿� 鞚胳儊頄堨姷雼堧嫟.
鞛 霕愲姅鞖挫榿歆€響滊姅氤搓碃霅橃 鞎婌晿鞀惦媹雼�.

氤搓碃靹滌棎電� 2025 鞓奠厴鞚胳劶韹半笇頂岆灉, 甏€霠� 靾橃儊瓿勳暯氚� 靾橃爼霅� 旎劋韺� 瓿勳暯鞐� 雽€頃� 斓滌嫚攵€靻嶌劀臧€ 韽暔霅橃柎鞛堨姷雼堧嫟.

Positive

All accelerated options remain non-exercisable until shareholder approval, providing an investor safeguard against immediate dilution.
Extension of CAO agreement through year-end secures continuity in a key finance role at a low incremental cost.

Negative

Front-loaded share-based compensation expense from accelerated vesting could pressure near-term reported earnings.
Potential dilution of up to ~1.36 million shares (options plus restricted stock) once shareholder approval is obtained.

Insights

TL;DR Acceleration increases current share-based comp expense and potential dilution; options still contingent on shareholder approval.

The board鈥檚 decision brings forward the vesting schedule for 965,000 options and 390,000 restricted shares. While this rewards leadership and directors immediately, it concentrates expense recognition into Q3 FY25 under ASC 718. Dilution risk is moderate because option exercise cannot occur until shareholders approve the 2025 Plan; absent approval, all options are void. The consulting agreement extension modestly raises fixed obligations (extra $15k maximum termination fee) but secures continuity in the CAO role through year-end. Overall impact on valuation is limited and largely accounting-based, not cash.

TL;DR Governance-neutral action; immaterial cash outflow, minor potential dilution, contingent on shareholder vote.

From an investor鈥檚 lens, the accelerated vesting signals confidence in management but does not alter core fundamentals鈥攏o revenue, margin or pipeline updates were provided. Total underlying shares (鈮�1.36 million) represent a modest fraction of ATNF鈥檚 46 million basic shares outstanding (per last 10-Q), implying <3% possible dilution if fully exercised/issued. Because exercise is blocked pending shareholder approval, immediate market impact should be small. The consulting amendment adds negligible cost. I view the filing as routine housekeeping rather than a catalyst.

臧€靻嶍檾霅� 氩犾姢韺� 鈥� 鞛勳洂霌�: 鞚挫偓須岆姅 CEO 敫旊爤鞏� 臁半崢瓿� CAO 鞐愲Ν 氚� 霠岉姼鞐愱矊 2025雲� 6鞗� 17鞚检棎攵€鞐悳 (i) 435,000欤� 鞀ろ啞鞓奠厴(頄夓偓臧€瓴� $0.9290, 10雲� 毵岅赴)瓿� (ii) 175,750欤� 鞝滍暅欤检嫕鞚� 鞝勳暋氩犾姢韺呾潉臧€靻嶍檾頄堨姷雼堧嫟.
臧€靻嶍檾霅� 氩犾姢韺� 鈥� 牍勳瀯鞗� 鞚挫偓霌�: 3氇呾潣霃呺 鞚挫偓鞐愱矊 2025雲� 6鞗� 17鞚检棎攵€鞐悳 530,000欤� 鞓奠厴(霃欖澕頄夓偓臧€瓴� $0.9290)瓿� 214,579欤� 鞝滍暅欤检嫕鞚� 氩犾姢韺呺弰臧€靻嶍檾霅橃棃鞀惦媹雼�.
欤检＜鞀轨澑頃勳殧: 雮橃姢雼� 攴滌爼瓿� 須岇偓鞚� 2025 鞓奠厴鞚胳劶韹半笇頂岆灉鞐� 霐半澕, 臧€靻嶍檾霅� 鞓奠厴鞚€ 欤检＜臧€ 2025 頂岆灉鞚� 鞀轨澑頃� 霑岅箤歆€ 頄夓偓頃� 靾� 鞐嗢姷雼堧嫟. 鞀轨澑氚涭 氇豁晿氅� 毂勴儩鞚茧攵€韯� 1雲� 雮挫棎氇摖鞓奠厴鞚� 旆唽霅╇媹雼�.
旎劋韺� 瓿勳暯靾橃爼: 2025雲� 7鞗� 12鞚�, 須岇偓鞕€ 鞐愲Ν 氚� 霠岉姼, EVL Consulting, LLC電� 氚� 霠岉姼鞚� 鞛勳洂旎劋韺� 瓿勳暯鞚� 2025雲� 12鞗� 31鞚缄箤歆€ 鞐办灔頃橁碃臁瓣赴頃挫 靾橃垬耄岆ゼ $10,000鞐愳劀 $25,000搿� 鞚胳儊頄堨姷雼堧嫟.
鞛 霕愲姅鞖挫榿歆€響滊姅氤搓碃霅橃 鞎婌晿鞀惦媹雼�.

07/14/2025 - 05:25 PM

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Howe Kelly Campbell

(Last)

(First)

(Middle)

200 E. RANDOLPH DR.

(Street)

CHICAGO

60601

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
07/01/2025

3. Issuer Name and Ticker or Trading Symbol
JONES LANG LASALLE INC [ JLL ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Financial Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	669	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Restricted Stock Units	02/15/2025⁽¹⁾	02/15/2027⁽¹⁾	Common Stock	2,477⁽¹⁾	$0⁽²⁾	D
Restricted Stock Units	02/15/2027⁽³⁾	02/15/2027⁽³⁾	Common Stock	1,592	$0⁽²⁾	D
Restricted Stock Units	02/15/2026⁽⁴⁾	02/15/2028⁽⁴⁾	Common Stock	3,143	$0⁽²⁾	D

Explanation of Responses:

1. On April 5, 2024, the Reporting Person was granted 3,714.00 restricted stock units vesting with respect to one third of the shares on each of February 15, 2025, February 15, 2026, and February 15, 2027. On February 15, 2025, 1,237.00 restricted stock units vested and were exercised and released.

2. Restricted stock units convert into an equal number of shares of common stock.

3. On April 5, 2024, the Reporting Person was granted 1,592.00 restricted stock units vesting with respect to all shares on February 15, 2027.

4. On April 4, 2025, the Reporting Person was granted 3,143.00 restricted stock units vesting with respect to one third of the shares on each of February 15, 2026, February 15, 2027, and February 15, 2028.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney. This Form 3 is being filed late due to a delay in obtaining the Reporting Person's EDGAR filing codes.

	/s/ Alan K. Tse, attorney-in-fact for Kelly Howe	07/14/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

How many 180 Life Sciences (ATNF) options had vesting accelerated?

The Board accelerated vesting of 965,000 stock options granted to executives and non-executive directors.

What is the exercise price of the accelerated options?

All options have an exercise price of $0.9290 per share, the market close on 17 June 2025.

Can the newly vested options be exercised immediately?

No. Shareholder approval of the 2025 Option Incentive Plan is required; without it, the options will be cancelled.

How many restricted shares vested as a result of the Board action?

A total of 390,329 restricted shares (executive and director grants combined) vested in full on 11-12 July 2025.

What changes were made to Eric Van Lent鈥檚 consulting agreement?

The term was extended to 31 December 2025 and the termination fee increased from $10,000 to $25,000.

Does the filing affect 180 Life Sciences鈥� cash position?

The actions are primarily non-cash accounting events; only the higher termination fee could lead to a modest future cash outflow.

AG真人官方

[Form 3] Jones Lang LaSalle, Inc. Initial Statement of Beneficial Ownership

Insights

FAQ

How many 180 Life Sciences (ATNF) options had vesting accelerated?

What is the exercise price of the accelerated options?

Can the newly vested options be exercised immediately?

How many restricted shares vested as a result of the Board action?

What changes were made to Eric Van Lent鈥檚 consulting agreement?

Does the filing affect 180 Life Sciences鈥� cash position?

NYSE:JLL

JLL Rankings

JLL Latest News

JLL Latest SEC Filings

JLL Stock Data

AG真人官方

Trending News

[Form 3] Jones Lang LaSalle, Inc. Initial Statement of Beneficial Ownership

Insights

Compensation Analyst neutral

Portfolio Manager neutral

FAQ

How many 180 Life Sciences (ATNF) options had vesting accelerated?

What is the exercise price of the accelerated options?

Can the newly vested options be exercised immediately?

How many restricted shares vested as a result of the Board action?

What changes were made to Eric Van Lent鈥檚 consulting agreement?

Does the filing affect 180 Life Sciences鈥� cash position?

NYSE:JLL

JLL Rankings

JLL Latest News

JLL Latest SEC Filings

JLL Stock Data